卡介菌多糖核酸联合泛昔洛韦治疗复发性生殖器疱疹的疗效及预防复发作用

目的：探讨卡介菌多糖核酸联合泛昔洛韦治疗复发性生殖器疱疹的疗效及预防复发作用。方法：选择70例复发性生殖器疱疹随机分为两组（对照组与联合组）。两组均予以口服泛昔洛韦片0.25g,2次/d,连用10d;后改为0.125g,2次/d,整个疗程共3个月。联合组在此基础上予以卡介菌多糖核酸1mL肌注,2次/周,连用3个月。对照组患者仅予以口服泛昔洛韦,剂量及疗程同联合组。观察两组患者治疗后临床效果及药物不良反应,并随访治疗结束后半年及1年内的复发率。结果：联合组治疗后临床总有效率为77.14%,明显高于对照组的42.86%（χ^2=8.57,P〈0.01）。联合组和对照组治疗期间出现药物不良反应6例和4例,症状均较轻,两组比较无统计学差异（χ^2=0.47,P〉0.05）。治疗结束后对治疗有效者均随访半年及1年内的复发率,联合组的复发率均明显低于对照组（P〈0.05或P〈0.01）。结论：卡介菌多糖核酸联合泛昔洛韦治疗复发性生殖器疱疹取得了较好效果,不良反应轻,并可降低其复发率,具有治疗和预防复发双重作用。     

中西医结合治疗复发性生殖器疱疹临床疗效观察

目的:观察中西医结合治疗复发性生殖器疱疹的临床疗效。方法:将100例复发性生殖器疱疹患者分为两组,治疗组50例,采用知柏地黄汤加减配合穴位自血疗法、口服泛昔洛韦片治疗;对照组50例,采用口服泛昔洛韦片治疗。结果:治疗组的总有效率为98.0%;对照组总有效率为76.0%,两组比较有显著性差异(P<0.05)。结论:中西医结合配合穴位自血疗法治疗复发性生殖器疱疹比单纯西药治疗治愈率更高,而且能明显降低复发率。     

泛昔洛韦联合膦甲酸钠对复发性生殖器疱疹患者免疫功能的影响

目的 研究泛昔洛韦联合膦甲酸钠对复发性生殖器疱疹患者免疫功能的影响.方法 选择2016年1月—2019年1月我院的82例复发性生殖器疱疹患者,随机分为2组.对照组口服泛昔洛韦治疗,观察组联合静脉滴注膦甲酸钠治疗.比较2组的免疫功能、复发情况和不良反应情况.结果 观察组的有效率明显高于对照组(P＜0.05);2组治疗后的...     

扶正解毒清热汤治疗复发性生殖器疱疹40例分析

目的:观察扶正解毒清热汤治疗复发性生殖器疱疹的临床疗效。方法:将80例复发性生殖器疱疹患者随机分为治疗组(40例)和对照组(40例),治疗组运用扶正解毒清热汤加盐酸泛昔洛韦片治疗,对照组口服盐酸泛昔洛韦片。对两组患者的临床疗效,发作期的止疱时间、水疱消失时间、结痂时间、脱痂时间以及随访期间复发率进行统计与对比。结果:中西药组疗效优于西药组,复发率低于西药组。结论:治疗组治疗复发性生殖器疱疹的临床疗效优于对照组,值得临床推广使用。     

伐昔洛韦联合胸腺肽肠溶片间歇疗法预防复发性生殖器疱疹疗效观察

目的探讨治疗复发性生殖器疱疹的最佳方法。方法将入选的70例复发性生殖器疱疹患者按就诊顺序随机分成2组,对照组35例,口服伐昔洛韦0.3g,2次/d,连服6d;治疗组35例,口服伐昔洛韦0.3g,2次/d,每月连服6d,胸腺肽肠溶片10mg,3次/d,每月连服14d。两组患者的疗程均为4个月,治疗结束后随访6个月。结果在4个月治疗期间,治疗组复发率(14.72%)明显低于对照组(80.65%);在6个月随访期间,治疗组复发率(52.94%)也明显低于对照组(90.32%),差异均有统计学意义(P均<0.05)。结论伐昔洛韦联合胸腺肽肠溶片间歇疗法治疗复发性生殖器疱疹可有效控制疱疹复发,疗效较好,且治疗方法简单,患者的依从性较好。     

伐昔洛昔联合甘露聚糖肽治疗复发性生殖器疱疹疗效观察

目的观察伐昔洛韦胶囊联合甘露聚糖肽针剂治疗复发性生殖器疱疹的疗效。方法治疗组45例口服伐昔洛韦胶囊0.3g/次,2次/d;甘露聚糖肽针5mg加利多卡因0.5mL局部皮下注射,3日1次,共10次。对照组40例予口服伐昔洛韦胶囊0.3g/次,2次/d。疗程均为1个月。治疗结束,随访1年。结果治疗组复发率22.2%,低于对照组复发率55.0%,无明显的不良反应。结论伐昔洛韦胶囊联合甘露聚糖肽针治疗生殖器疱疹疗效满意。     

转移因子联合阿昔洛韦治疗频发性生殖器疱疹疗效观察

目的探讨转移因子联合阿昔洛韦治疗频发性生殖器疱疹的疗效。方法试验组46例,转移因子口服液10 mL2次/d,阿昔洛韦缓释片0.4 g,3次/d;对照组40例,阿昔洛韦缓释片0.4 g,3次/d;两组均治疗至HSV-2 IgG,IgM抗体阴性,但最长不超过6个月。结果试验组3个月、6个月后HSV-2 IgG,IgM抗体的阴转率均比对照组高(P(0.05)。结论转移因子可提高频发性生殖器疱疹的疗效。     

参芪片联合伐昔洛韦治疗复发性生殖器疱疹的研究

目的探讨参芪片联合伐昔洛韦治疗复发性生殖器疱疹的疗效。方法对48例复发性生殖器疱疹患者随机分为治疗组和对照组,治疗组同时口服参芪片与伐昔洛韦3个月,对照组口服伐昔洛韦3个月。观察治疗前后1年期间复发的次数和症状消退时间。结果治疗后对照组与治疗组复发次数有显著性差异,症状消退时间的差异有显著性。结论参芪片联合法昔洛韦可以降低复发性生殖器疱疹的复发次数。     

三种方法治疗带状疱疹疗效观察

目的寻找更安全、有效、经济的治疗带状疱疹及神经痛的方法。方法91例患者随机分为三组进行对比观察.分别于疗程第5,10天观察症状及体征的变化和不良反应。A组口服泛昔洛韦250mg,3次/d,复方甘草酸苷片75mg,3次/d;B组口服泛昔洛韦250mg,3次/d;C组口服复方甘草酸苷片75mg,3次/d。结果三组在结痂起始、止痛起效、疼痛消失时间上有显著性差异;有效率分别为96.77%,86.67%和73.33%;不良反应分别为3.2%,3.3%和0。结论泛昔洛韦和复方甘草酸苷联合应用是治疗带状疱疹和神经痛的一种安全、有效、也较为经济的方法。     

三种方法预防复发性生殖器疱疹疗效观察

目的探讨治疗复发性生殖器疱疹的有效方法。方法 A组42例,伐昔洛韦0.3g,1次/d;B组41例,阿昔洛韦0.4g,2次/d;C组37例,阿昔洛韦0.4g,转移因子6mg,2次/d,疗程均为6个月。结果各组复发率分别为23.80%,29.30%,18.90%,各组间差异无统计学意义。结论采用6个月抑制疗法治疗生殖器疱疹,可有效控制复发。     

伐昔洛韦抑制疗法和间歇疗法预防生殖器疱疹复发作用比较

目的　比较伐昔洛韦每日抑制疗法和间歇疗法对预防生殖器疱疹复发的作用。方法　 65例复发性生殖器疱疹患者按不同复发频度分层后以半随机方式分配至间歇疗法组 (A组 )和每日抑制疗法组 (B组 )。A组 3 4例 ,当疱疹复发时口服伐昔洛韦 3 0 0mg ,2次 /d ,连服 6天 ;B组 3 1例 ,口服伐昔洛韦 3 0 0mg ,1次 /d ,连服 4个月。治疗后观察随访 6个月。结果　在 4个月治疗期间以及其后 6个月随访期间 ,B组每半年平均复发次数均显著低于A组 (P均 <0 .0 0 1)。结论　伐昔洛韦每日抑制疗法对预防和延迟生殖器疱疹复发具有显著作用 ,疗效明显优于间歇疗法。     

磷甲酸钠联合胸腺五肽治疗生殖器疱疹60例临床观察

目的评价磷甲酸钠联合胸腺五肽治疗生殖器疱疹的疗效和安全性。方法将入选的120例患者随机分为2组,治疗组60例,静滴磷甲酸钠250mg,并肌肉注射胸腺五肽1mg,均1次/d;对照组60例,口服伐昔洛韦300mg,2次/d,两组患者的疗程均为15d。结果两组治愈率均为100%,治疗组平均治愈时间(3.23±0.93)d明显短于对照组(4.35±1.04)d,差异有统计学意义(P<0.01)。治疗结束后6个月时治疗组复发率(28.33%)均明显低于对照组(46.67%),差异也有统计学意义(P<0.05)。治疗组仅有轻微的静脉刺痛、一过性低热和胃肠道反应,未影响疗程。结论磷甲酸钠联合胸腺五肽治疗生殖器疱疹能有效减少复发,安全性好。     

泛昔洛韦与阿昔洛韦治疗老年带状疱疹疗效比较

目的：比较泛昔洛韦(FCV)与阿昔洛韦(ACV)治疗老年带状疱疹(HZ)的疗效。方法：应用开放、随机、平行对照的临床试验。患口服泛昔洛韦250mg，每日2次，共14天或静滴阿昔洛韦250mg，每日3次，共5天，改口服阿昔洛韦0．2，每日5次至14天。结果：两组在止疱时间、皮损愈合时间、疼痛开始缓解时间、疗后疼痛积分及后遗神经痛比率方面均无明显差异。7、14、21天治愈率、显效率比较差异无显性。未见明显不良反应。结论：口服泛昔洛韦250mg，每日2次与静滴及口服阿昔洛韦治疗老年带状疱疹同样有效、安全。     

Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial

BACKGROUND: Twice-daily therapy with famciclovir (FCV) was shown to be effective for episodic therapy for recurrent genital herpes in a large placebo-controlled trial. However, no study has been published to date comparing FCV and aciclovir (ACV). OBJECTIVES: We have evaluated the effectiveness of FCV vs. ACV in the treatment of recurrent genital herpes infection. METHODS: A multicentre, double-blind, double-placebo, randomized, parallel-design study, assessed for equivalence, was conducted. As the analysis was based on confidence intervals, a difference of lesion healing time between ACV and FCV (Delta) of 1.05 days with a standard deviation of 2.30 days was chosen. Two hundred and four outpatients were included. Patients self-initiated oral therapy with 125 mg of FCV twice daily or ACV 200 mg five times daily for 5 days. The principal end-point of the study was the complete healing of lesions. Duration of the complete resolution of all symptoms, and safety were also considered. RESULTS: The mean healing time was 5.1 days and 5.4 days for FCV and ACV, respectively, with a crude value of Delta = 0.25 days (CI 95%: -0.32; 0.82) in the intent-to-treat population. Therefore, the confidence interval for the difference between the two treatments lies entirely within the equivalence range (-1.05-1.05). The value of Delta in the per-protocol population [0.35 day (CI 95%: -0.24; 0.93)] was comparable between the two groups. No differences were detected in the proportion of patients having complete healing at the different days of evaluation as well as in the duration until the complete resolution of all the symptoms. The frequency, nature and severity of adverse events did not differ among the two treatment groups. CONCLUSIONS: Twice-daily FCV was as effective and safe in the treatment of recurrent genital herpes simplex virus infection as five times daily ACV.     

伐昔洛韦不同用药方案治疗复发性生殖器疱疹的疗效观察

目的:探讨分析伐昔洛韦不同用药方案治疗复发性生殖器疱疹的临床疗效。方法:选取我院于2011年2月至2013年4月收治的152例复发性生殖器疱疹的患者,将所有患者按随机数法分为实验组与对照组,两组均为76例。所有患者均服用伐昔洛韦进行治疗,对照组连续服用7d,2次/d,300mg/次,实验组连续服用5d,2次/d,500mg/次。对比分析两组的临床疗效及治疗过程中不良反应的发生情况。结果:实验组与对照组第1d、第3d、第5d、第7d基于积分的有效率的差异比较无统计学意义(P>0.05);实验组治疗第1d HSV培养阳性率要明显低于对照组(P<0.05),两组第2d HSV培养阳性率的差异比较无统计学意义(P>0.05);实验组与对照组治疗过程中不良反应发生率的差异比较无统计学意义(P>0.05)。结论:增加伐昔洛韦的单次用量治疗复发性生殖器疱疹效果显著,单纯疱疹病毒在皮损局部的存在时间明显缩短,且不良反应的发生率未明显提升。     

泛昔洛韦治疗发作期复发性生殖器疱疹80例随机对照观察

目的探讨泛昔洛韦1日疗法治疗发作期复发性生殖器疱疹的疗效及安全性。方法采用随机、非安慰剂对照临床实验比较泛昔洛韦1日疗法(1000mg,2次/d,共1d)与传统5日疗法(125mg,2次/d,共5d)的疗效及安全性。结果共160例发作期复发性生殖器疱疹患者参加试验。1日疗法和5日疗法的皮损愈合时间分别为(4.02±0.76)和(3.90±0.89)天,症状消退时间为(3.42±0.64)和(3.46±0.83)天,痊愈时间为(4.43±0.47)和(4.35±0.94)天,皮损顿挫比率分别为31.25%和22.50%,差异均无统计学意义(P均>0.05)。以头痛、消化道症状为主,不良反应发生率分别为28.75%和25.00%,差异也无统计学意义(P>0.05)。结论泛昔洛韦1日疗法治疗发作期复发性生殖器疱疹安全有效,治疗方便。     

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.

OBJECTIVE: To compare the efficacy and safety of twice daily valaciclovir with five times daily aciclovir in the treatment of an episode of recurrent genital herpes simplex virus (HSV) infection in immunocompetent individuals. METHODS: 739 patients with a history of recurrent genital HSV infection received either oral valaciclovir (500 mg twice daily) or aciclovir (200 mg five times daily) for 5-days for treatment of their next recurrent episode in a controlled, randomised, double blind trial. Patients self initiated therapy at the first signs and/or symptoms of the HSV recurrence, then were assessed in clinic on five occasions over 7 days, and twice weekly thereafter until lesions had healed. Safety was evaluated through adverse experience reports and haematology and biochemistry monitoring. RESULTS: No significant differences were detected between valaciclovir and aciclovir for the primary endpoint, the duration of all signs and symptoms which included lesion healing and pain/discomfort. The hazard ratio [95% confidence interval] for valaciclovir v aciclovir was 0.93 [0.79, 1.08]. Lesion healing time was similar in each treatment group (hazard ratio valaciclovir v aciclovir 0.96 [0.80, 1.14]). The odds ratio of valaciclovir v aciclovir in preventing the development of vesicular/ulcerative lesions was 1.08 [0.82, 1.42]. Percentages of patients in whom all HSV cultures were negative were similar in the valaciclovir and aciclovir groups at 59% and 54% respectively; for patients having equal to or more than one positive culture result after treatment initiation, cessation of virus shedding was similarly rapid for the two treatments (hazard ratio 0.98 [0.75, 1.27]). The safety profiles of valaciclovir and aciclovir were comparable with adverse experiences being infrequent and generally mild. CONCLUSION: This study has demonstrated that valaciclovir 500 mg twice daily is equivalent in efficacy to aciclovir 200 mg five times daily as episodic treatment of recurrent genital HSV infection. Valaciclovir maintains the established efficacy and safety of aciclovir but offers a much more convenient twice daily dosing regimen.     

不同剂量和疗程伐昔洛韦治疗复发性生殖器疱疹的随机双盲研究

目的 比较不同剂量和疗程伐昔洛韦治疗复发性生殖器疱疹的疗效和安全性。方法 选择复发性生殖器疱疹为研究对象,采用多中心、随机、双盲、对照临床研究。试验组伐昔洛韦每天2次,每次500 mg,口服5天,对照组伐旨洛韦每天2次,每次300 mg,口服7天。分别于用药前及用药后第1天、第2天取疱液或创面分泌物行疱疹病毒细胞培养,并于用药后第1、2、7天随访观察疗效和不良反应。结果 入组142例,全分析集(FAS)分析142例,符合方案集(PPS)分析133例。治疗后第1、2、7天,试验组和对照组的症状体征积分下降值及有效率比较差异均无统计学意义(P>0.05)。FAS集分析单纯疱疹病毒(HSV)的培养阳性率,治疗后第1天试验组由87.50%下降到28.85%,对照组由92.86%下降到54.55%,两组间差异有统计学意义(P=0.007)。PPS集分析HSV的培养阳性率,治疗后第1天试验组由90.00%下降到28.00%,对照组由92.59%下降到55.56%,两组比较差异有统计学意义(P=0.005)。试验组和对照组不良反应发生率分别为0%和4.23%。结论 加大伐昔洛韦用量治疗复发性生殖器疱疹能显著提高治疗后第1天HSV的清除率,缩短HSV在皮损局部的存在时间。